Su Jun Lee

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests
    Su Jun Lee
    National Institutes of Health, National Institute of Environmental Health Science Center, NC 27709, USA
    Pharmacogenomics 6:357-71. 2005
  2. pmc Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients
    Wai Johnn Sam
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA
    Transplantation 94:971-7. 2012
  3. ncbi request reprint Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups
    Su Jun Lee
    Human Metabolism Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Pharmacogenetics 13:461-72. 2003
  4. ncbi request reprint Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype
    Su Jun Lee
    Human Metabolism Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    J Pharmacol Exp Ther 313:302-9. 2005
  5. ncbi request reprint Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition
    Su Jun Lee
    Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
    J Clin Pharmacol 46:515-26. 2006
  6. pmc The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression system
    Su Jun Lee
    Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    Pharmacogenet Genomics 17:169-80. 2007
  7. pmc Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients
    Wai Johnn Sam
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD, USA
    Transplantation 92:1342-7. 2011
  8. pmc A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
    Su Jun Lee
    Department of Clinical Chemistry, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Drug Metab Dispos 35:67-71. 2007
  9. ncbi request reprint The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals
    Su Jun Lee
    Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, Korea
    Drug Metab Dispos 35:2095-101. 2007
  10. ncbi request reprint Discovery of new potentially defective alleles of human CYP2C9
    Joyce Blaisdell
    Laboratory of Pharmacology and Chemistry, Human Metabolism Section, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA, DNA
    Pharmacogenetics 14:527-37. 2004

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests
    Su Jun Lee
    National Institutes of Health, National Institute of Environmental Health Science Center, NC 27709, USA
    Pharmacogenomics 6:357-71. 2005
    ....
  2. pmc Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients
    Wai Johnn Sam
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD 20892, USA
    Transplantation 94:971-7. 2012
    ..We further examined to see whether these polymorphisms were also associated with SRL-induced dyslipidemia...
  3. ncbi request reprint Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups
    Su Jun Lee
    Human Metabolism Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Pharmacogenetics 13:461-72. 2003
    ....
  4. ncbi request reprint Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype
    Su Jun Lee
    Human Metabolism Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    J Pharmacol Exp Ther 313:302-9. 2005
    ..The new genetic tests will be useful in future clinical studies to investigate genotype/phenotype associations...
  5. ncbi request reprint Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition
    Su Jun Lee
    Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA
    J Clin Pharmacol 46:515-26. 2006
    ..New polymerase chain reaction-based genotyping methods for functionally defective CYP3A5*6, *8, *9, and *10 alleles were developed in this study. These assays will be useful for CYP3A5 genotype analysis in future clinical studies...
  6. pmc The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression system
    Su Jun Lee
    Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    Pharmacogenet Genomics 17:169-80. 2007
    ..We sequenced CYP26A1 in racially diverse individuals and assessed the metabolism of retinoic acid by newly identified coding alleles of CYP26A1 in a recombinant system...
  7. pmc Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients
    Wai Johnn Sam
    Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD, USA
    Transplantation 92:1342-7. 2011
    ....
  8. pmc A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
    Su Jun Lee
    Department of Clinical Chemistry, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Drug Metab Dispos 35:67-71. 2007
    ..No additional examples of this allele were identified. In summary, individuals carrying the rare CYP3A5*11 allele are predicted to have lower metabolism of CYP3A5 substrates than individuals expressing CYP3A5*3...
  9. ncbi request reprint The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals
    Su Jun Lee
    Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, Korea
    Drug Metab Dispos 35:2095-101. 2007
    ..09 in AUC). In summary, the heterozygous CYP3A4(*)1/(*)18 does not appear to cause a significant change of midazolam disposition in vivo; however, the clinical relevance of CYP3A4(*)18/(*)18 remains to be evaluated...
  10. ncbi request reprint Discovery of new potentially defective alleles of human CYP2C9
    Joyce Blaisdell
    Laboratory of Pharmacology and Chemistry, Human Metabolism Section, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA, DNA
    Pharmacogenetics 14:527-37. 2004
    ..Further clinical studies are needed to determine the effect of these new polymorphisms on the metabolism of CYP2C9 substrates...
  11. ncbi request reprint Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations
    Sang Seop Lee
    Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, 655 165 Gaegum dong, Jin gu, Busan 614 735, South Korea
    Ther Drug Monit 29:455-9. 2007
    ..2%, 95% confidence interval 6.2-8.2) (P = 0.074). These results obtained from a large number of subjects can be used in comparative studies with other ethnic groups in future clinical research...
  12. ncbi request reprint Identification and functional assessment of BCRP polymorphisms in a Korean population
    Sang Seop Lee
    Department of Pharmacology, PharmacoGenomics Research Center, College of Medicine, Inje University, 633 165 Gaegum Dong, Jin gu, Busan 614 735, Korea
    Drug Metab Dispos 35:623-32. 2007
    ..Genetic polymorphisms of BCRP were found to be very common in Koreans, as well as in other ethnic groups. Comparative analyses among three Asian populations revealed different frequencies for the four functional BCRP variants...